Back to News
Market Impact: 0.3
Labcorp To Buy Myriad Genetics' Prenatal Testing Business For $210 Mln
Source: Nasdaq
M&A & RestructuringHealthcare & Biotech
LabCorp agreed to acquire Myriad Genetics’ Prenatal Health testing business for $210 million in cash, plus the value of inventory at closing. The available article text provides no further terms, expected financial impact, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
LH0.30
MYGN0.10
More News
- Why is Myriad Genetics stock surging today?
- Elon Musk says SpaceX and Tesla exploring largest merger in history
- Elon Musk says Tesla and SpaceX are weighing a $3.5 trillion merger—without him in the room
- Capital One's strong quarter and progressing Discover integration are rewarded on Wall Street
- SpaceX Earnings Blow Past Wall Street Estimates
- Tesla’s stock rises as Elon Musk drops new clues about a possible SpaceX merger
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features, UI Improvements, and Chat Optimizations
- Selecting an AI Research Platform for Institutional Investors